LSVT LOUD — Increased Vocal Loudness for Hypokinetic Dysarthria
Increase vocal loudness (sound pressure level) and self-perception of loudness using the LSVT LOUD protocol across speech tasks of increasing complexity, addressing hypokinetic dysarthria in Parkinson's disease.
The Four Questions
Full Goal
Within the LSVT LOUD protocol delivered at the certified protocol intensity (4 sessions per week × 4 weeks = 16 sessions, plus daily homework), beginning with maximum-effort vowel prolongations and hierarchical speech tasks (words, phrases, reading, conversation), patient will produce a sustained vowel with increased loudness, defined as ≥10 dB SPL gain from baseline at 30 cm, generalize loudness to speech tasks at increasing complexity, and self-calibrate loudness to functional contexts with ≥10 dB SPL increase on sustained vowel maintained at end of treatment and at 6-month follow-up, and patient self-rating of communicative ease (Communicative Effectiveness Survey or equivalent) improved by ≥10 points from baseline, as measured by calibrated sound-level meter at 30 cm during sustained vowel, reading passage, and monologue tasks at baseline, weekly during treatment, end of treatment, and 6-month follow-up; client self-report on validated communicative effectiveness measure.
Individualization Guidance
Before using this goal, verify:
- Clinician is LSVT-certified. LSVT LOUD is a trademarked, protocol-defined intervention. Delivering “LSVT-like” therapy without certification is neither LSVT LOUD nor evidence-based — it is a different intervention. Either certify and deliver the protocol, or write a different dysarthria goal using the broader systematic-review literature.
- Dosage is non-negotiable. The published evidence base is for 4×/week × 4 weeks intensity. Delivering 1-2×/week loses the intensive-practice mechanism the protocol depends on. If insurance, schedule, or patient capacity does not allow protocol dosage, document the deviation and discuss the modified protocol research (LSVT LOUD X, telehealth delivery).
- Diagnostic appropriateness. LSVT LOUD has the strongest evidence in idiopathic Parkinson’s disease. Evidence is growing for Parkinson-plus syndromes (MSA, PSP), MS, stroke-related dysarthria, and pediatric dysarthria — but outcomes and protocols vary. Document the diagnosis and cite the relevant evidence base.
- Cognitive screening. Patients with significant cognitive impairment (advanced PD with dementia, severe MCI) may not tolerate or benefit from the intensive protocol. The cognitive load of the calibration component (self-monitoring loudness against target) requires intact executive function.
- Daily homework adherence. The 4× clinic sessions + 2 homework sessions per non-clinic day model assumes the patient has cognitive, motor, and social capacity to complete homework. Caregiver support may be needed. Document the home-practice support plan.
- Voice symptom monitoring. The maximum-effort principle produces vocal load. Monitor for vocal strain or pathology, particularly in patients with pre-existing voice issues. Refer to laryngology if hoarseness or other symptoms appear.
- Sound-level meter calibration. The 30 cm distance, microphone type, and ambient noise environment all affect SPL readings. Use a calibrated meter, document the conditions, and replicate them across measurements.
Clinical Notes
The dual criterion — sustained vowel SPL gain AND patient-reported communicative ease — captures both the impairment-level change (loudness) and the functional outcome (communication) that the protocol targets. SPL gain without functional improvement is incomplete; functional improvement without SPL gain calls the mechanism into question.
The 6-month follow-up requirement reflects LSVT LOUD’s distinctive evidence base: the literature documents maintenance of gains at 6 and 24 months in a substantial proportion of patients. Goals that only measure end-of-treatment outcomes miss what makes this protocol clinically meaningful.
The “self-calibrate loudness to functional contexts” component addresses a common late-phase challenge: patients can produce loud voice in the clinic but underutilize it in conversation. The calibration phase of the protocol explicitly trains patients to monitor and adjust their own loudness in real time — that’s the generalization mechanism.
LSVT LOUD is one of the most-studied behavioral interventions in dysarthria. The evidence base is broad and the protocol is highly specified. This is paradoxically why goals can be poorly written: clinicians treat the protocol as the goal and forget to specify the patient-specific functional outcomes. Write both.
For CMS skilled-service documentation: the clinician’s judgment about calibration target, hierarchy progression, homework design, and adjustment based on weekly SPL data is the skilled component. Recording sessions and replaying them does not require skilled SLP service.
This is a high-effort, high-evidence intervention. For patients who cannot complete the protocol dosage, alternative goals targeting loudness or intelligibility through different mechanisms (e.g., SpeakOUT!, pacing strategies, AAC supplementation) are appropriate and should be considered without framing them as “less than” LSVT.
Related Goals
- Resonant Voice Production for Muscle Tension Dysphonia — Adult — contrast goal for non-neurogenic voice impairment
- Gender-Affirming Voice — Client-Defined Voice Targets — contrast goal for identity-affirming (non-pathology) voice work
Evidence Base
- ASHA Practice Portal: Dysarthria in Adults
- Ramig, L.O., Sapir, S., Countryman, S., et al. (2001). Intensive voice treatment (LSVT) for patients with Parkinson's disease: A 2 year follow up. Journal of Neurology, Neurosurgery & Psychiatry, 71(4).
- Fox, C.M., Ramig, L.O., Ciucci, M.R., Sapir, S., McFarland, D.H., & Farley, B.G. (2006). The science and practice of LSVT/LOUD: Neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Seminars in Speech and Language, 27(4).
- Ramig, L.O., Halpern, A., Spielman, J., Fox, C., & Freeman, K. (2018). Speech treatment in Parkinson's disease: Randomized controlled trial (RCT). Movement Disorders, 33(11).
- Yorkston, K.M., Hakel, M., Beukelman, D.R., & Fager, S. (2007). Evidence for effectiveness of treatment of loudness, rate, or prosody in dysarthria: A systematic review. Journal of Medical Speech-Language Pathology, 15(2).
- Sapir, S., Ramig, L.O., & Fox, C.M. (2011). Intensive voice treatment in Parkinson's disease: Lee Silverman Voice Treatment. Expert Review of Neurotherapeutics, 11(6).
- Wight, S., & Miller, N. (2015). Lee Silverman Voice Treatment for people with Parkinson's: Audit of outcomes in a routine clinic. International Journal of Language & Communication Disorders, 50(2).
- LSVT Global — clinician training and certification
- CMS Medicare Benefit Policy Manual, Chapter 8 (skilled SLP services)